TRISTEL PLC - Interim Results скачать в хорошем качестве

TRISTEL PLC - Interim Results

To be informed of all TRISTEL PLC's upcoming presentations, register at InvestorMeetCompany: https://www.investormeetcompany.com/t... 0:00 Introduction 1:45 Overview 4:12 Financial Performance 14:07 USA Performance 22:29 Investing for Future Growth 34:52 Q&A Tristel PLC (AIM:TSTL) delivered a strong H1 FY2026 investor update, reporting record revenue of £25.6 million, up 14 percent, driven by volume growth across the UK and international markets, alongside expanding US operations. Adjusted EBITDA rose 17 percent with margins at 29 percent, comfortably above the 25 percent target, while adjusted profit before tax increased 11 percent to £5.5 million, reflecting operational leverage and disciplined cost control. Gross margin remained robust at 81 percent, with further efficiency gains expected from in sourced production. Cash generation was solid at £6.7 million, supporting a strong balance sheet, 25 percent return on capital employed, and a maintained progressive dividend policy with an interim dividend of 5.68 pence per share. US performance accelerated significantly, with sixfold revenue growth supported by the commercial launch of high level disinfection products for ultrasound and ophthalmology, expanding distribution partnerships, OEM collaborations, and growing inclusion in clinical guidelines. Management reaffirmed full year market expectations and outlined a clear growth strategy focused on geographic expansion, commercial headcount investment, clinical leadership, digital platform development, and new product innovation including VisiClean. With double digit revenue growth targets through 2030 and sustained EBITDA margin discipline, Tristel remains well positioned to scale its infection prevention platform, expand market share, and deliver long term shareholder value.